SCHEMBL16930794

SCHEMBL16930794

N#Cc1ccc(C(N)=NC=O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP15 Q460N3 1/20 0.46
▸ PARP10 Q53GL7 1/20 0.46
▸ PARP2 Q9UGN5 1/20 0.46
▸ CA2 P00918 3/20 0.46
▸ CA1 P00915 2/20 0.46
▸ NOS3 P29474 2/20 0.43
▸ NOS1 P29475 2/20 0.43
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ GSK3B P49841 2/20 0.42
▸ CA12 O43570 1/20 0.39
▸ CA3 P07451 1/20 0.39
▸ CA6 P23280 1/20 0.39
▸ CA9 Q16790 1/20 0.39
▸ CA14 Q9ULX7 1/20 0.39
▸ MAOA P21397 1/20 0.38
▸ MAOB P27338 1/20 0.38
▸ P4HB P07237 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.37
▸ MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4947766 0.78 NOS3 (0.50) PARP15PARP10PARP2CA2CA1
SCHEMBL1160894 0.78 NOS3 (0.50) PARP15PARP10PARP2CA2CA1
SCHEMBL1305151 0.76 NOS3 (0.53) PARP15PARP10PARP2CA2CA1
SCHEMBL16930801 0.75 CYP2D6 (0.48) MEN1KMT2AALDH1A1MAPTTDP1
SCHEMBL16930780 0.72 GRIN2B (0.51) MEN1KMT2AGSK3BMAPTL3MBTL1
SCHEMBL16930804 0.72 PRSS1 (0.48) CA2CA1NOS3NOS1CA12
SCHEMBL322070 0.71 PARP15 (0.78) PARP15PARP10PARP2CA2CA1
SCHEMBL16930799 0.70 TNF (0.50) CA2CA1MEN1KMT2AALDH1A1
SCHEMBL16930783 0.70 KDM1A (0.30) —
Formic Acid SCHEMBL27735467 0.70 CA2 (0.57) CA2CA1NOS3NOS1GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9716235-B2 9,10-bis[2-(p-substituted phenyl)pyrimidin-4-yl] anthracene compounds, methods of preparing the same, organic electroluminescent devices and organic electroluminescent display apparatus BOE TECHNOLOGY GROUP CO., LTD. (CN) 2017-07-25 — — US disclosed
US-20150214487-A1 9,10-Bis[2-(p-substituted phenyl)pyrimidin-4-yl] Anthracene Compounds, Methods of Preparing the Same, Organic Electroluminescent Devices and Organic Electroluminescent Display Apparatus BOE TECHNOLOGY GROUP CO., LTD. (CN) 2015-07-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150214487-A1 9,10-Bis[2-(p-substituted phenyl)pyrimidin-4-yl] Anthracene Compounds, Methods of Preparing the Same, Organic Electroluminescent Devices and Organic Electroluminescent Display Apparatus P2RY10, P2RY4, APRT PARP15 646/4885PARP10 254/4885PARP2 846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback